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Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre 
case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine 
effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) 
among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection 
patients to swab within seven days of symptom onset. We restricted the study population to those meeting the 
EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used 
logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), 
controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related 
hospitalisations,  number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence 
intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years 
and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the 
early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested 
a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season 
or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand 
its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to 
achieve acceptable levels of protection.  
Introduction  
 
Unlike the formulation of other vaccines, the formulation of seasonal influenza vaccines is reviewed annually by the World 
Health Organization (WHO) and frequently adapted to the constantly evolving nature of influenza viruses. 
 
How the vaccine performs in target group populations cannot be anticipated by pre-authorisation efficacy trials in healthy 
young adults, immunogenicity studies or the relatedness of vaccine and circulating viruses. Field influenza vaccine 
effectiveness (IVE) studies provide essential additional information to advise stakeholders on the performance of the 
vaccine, to contribute to vaccine strain selection process and to inform when additional measures, such as antivirals, are 
needed given a low observed effectiveness early in the season.  
 
In the European Union (EU) countries, the seasonal influenza vaccine is recommended annually for specific target groups, 
including those at risk of severe disease, the largest groups being older individuals (generally 60 or 65 years and above, 
depending on the country) and all those over six months of age with underlying medical conditions in the following 
categories: chronic respiratory and cardiovascular diseases, chronic metabolic disorders, chronic renal and hepatic 
diseases and immune system dysfunctions (congenital or acquired) [1]. 
 
In 2007, the European Centre for Disease Prevention and Control (ECDC) and a network of 18 public health institutes 
 Back to Table of Contents 
 Previous Next  
Page 1 of 8
01-02-2013http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20390
established the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project which monitors IVE each season 
in the EU and the European Economic Area (EEA) [2]. Currently 20 public health institutes from the EU and EEA are part 
of the I-MOVE network, which is coordinated by EpiConcept under the umbrella of ECDC [3]. One component of I-MOVE 
is a multicentre case–control study, which has provided IVE estimates each season since the pilot season in 2008/09 [4–
8]. All study sites follow a generic protocol [9]. 
 
During the pilot phase in the 2008/09 season, the pooled adjusted IVE estimates from the multicentre case–control study, 
restricted to individuals aged 65 years and above , suggested an overall IVE of 59.1% (95% confidence intervals (CI): 15.3 
to 80.3%). In the subsequent season 2009/10, an adjusted pandemic IVE of 71.9% (95% CI: 45.6 to 85.5) among all age 
groups was estimated and in the 2010/11 season an adjusted IVE of 56.2% (95% CI: 34.3 to 70.7) was calculated among 
the target group for vaccination [4,5,7]. 
 
The aim was to provide overall and age-specific IVE estimates among what is defined as the target group for vaccination 
in these countries [10–17]. We restricted the analysis to influenza A(H3), as this was the predominant strain during the 
season [18]. The 2011/12 seasonal influenza A(H3) vaccine virus for the northern hemisphere was A/Perth/16/2009 
(H3N2)-like virus. 
Methods 
  
The eight study sites included in the 2011/12 I-MOVE multicentre case–control study were based in France, Hungary, 
Ireland, Italy, Poland, Portugal, Romania and Spain. At each study site, practitioners already participating in the European 
Influenza Surveillance Network (EISN) were invited to take part in the study [19]. In addition, study sites in Hungary and 
Portugal invited practitioners outside the EISN network. 
 
The study population consisted of non-institutionalised influenza-like-illness (ILI) patients without contraindications for 
vaccination who were swabbed within less than eight days after symptom onset. Practitioners carried out naso-pharyngeal 
swabbing and collected information from patients consulting for ILI or, for France only, for acute respiratory infection (ARI). 
Only patients adhering to the EU ILI case definition were included (sudden onset of symptoms and at least one of the 
following four systemic symptoms: fever or feverishness, malaise, headache, myalgia; and at least one of the following 
three respiratory symptoms: cough, sore throat, shortness of breath) [20]. In all study sites, practitioners swabbed all 
elderly (60 or 65 years old and older) consulting for ILI, except for France where a proportion of elderly consulting for ARI 
were systematically selected for swabbing. Practitioners systematically selected patients from other age groups to swab 
using statistical sampling, except for Romania, where all patients consulting for ILI were swabbed. Hungary restricted their 
study population to those aged 18 years and over. 
 
All participants in the study gave oral or written consent, in adherence with country requirements for ethical approval at 
each study site. The study period began 15 days after the start of the respective 2011/12 seasonal influenza vaccination 
campaign in each country. 
 
Practitioners used standardised country-specific questionnaires to collect information on ILI signs and symptoms, sex, 
age, seasonal influenza vaccination in the 2011/12 and 2010/11 seasons, pregnancy, chronic conditions (including 
obesity, as defined in the participating countries), number of hospitalisations for chronic conditions in the past 12 months, 
receipt of antivirals (Spain and France excluded), and number of general practitioner (GP) visits in the past 12 months. 
Study sites included a question on belonging to the target group for vaccination, apart from France and Portugal, where 
this information was gathered using information on age, chronic conditions, and pregnancy. In addition, information related 
to target groups for vaccination was gathered in Portugal on whether the patient was a health professional or carer and a 
co-habitant or carer of a patient at-risk aged less than six months. 
 
Among ILI patients fulfilling the inclusion criteria, we defined a case of influenza as a study participant whose swab tested 
positive for influenza virus by reverse-transcription polymerase chain reaction (RT-PCR) or culture. We classified patients 
with swabs testing negative for influenza virus as controls.  
 
Swabs were tested for influenza at the respective country’s National Influenza Reference Laboratory. In France, Italy, and 
Spain, tests were also conducted in other laboratories participating in the National Influenza Sentinel Surveillance System. 
At all study sites a subset of isolates were genetically and/or antigenically characterised. Details of laboratory viral 
detection, typing, subtyping and variant analysis performed are described elsewhere [21]. 
 
We defined a person as vaccinated if they had received at least one dose of 2011/12 seasonal influenza vaccine more 
than 14 days prior to ILI/ARI symptom onset. All the others were classified as unvaccinated. 
 
The eight study teams sent their data to EpiConcept, where they were pooled and analysed. We carried out an analysis 
restricted to the A(H3) influenza type. We excluded controls presenting to the practitioner before the week of symptom 
onset of the first case and after the last case of influenza A(H3) in each country respectively. We restricted the study 
population to the target groups for vaccination. We compared the characteristics of cases and controls using chi-square 
tests, t-tests, Fisher's exact test or the Mann-Whitney test depending on the nature of the variable. 
 
We used Cochran's Q-test and the I2 index to test the heterogeneity between study sites [22]. 
 
We estimated the pooled IVE as 1 minus the odds ratio (OR) of being vaccinated in cases versus controls, using a one-
stage method with study site as fixed effect in the model.  
 
To estimate adjusted IVE, we used a logistic regression model including potential confounding factors: age (10-year age 
bands), sex, presence of at least one chronic condition (including pregnancy and obesity), at least one hospitalisation in 
the previous 12 months for the chronic condition, number of practitioner visits in the previous 12 months (0-1, 2-4 and ≥5 
visits) and month of symptom onset. 
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 We stratified IVE into three age groups (0–14, 15–59 and 60 years and above). Since the influenza season started 
unusually late in Europe, we studied IVE in the early and late phase of the season and by time since vaccination [23]. The 
early and late phases of the influenza season were defined as up to and including week 6 of 2012 and from week 7 
respectively, categories which allow for a similar sample size. In each of the two phases, we also calculated IVE by time 
since vaccination, with IVE estimates for symptom onset less than 93 days (around three months) since vaccination and 
93 days or more since vaccination. 
 
We conducted all statistical analysis using Stata version 12 (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP). 
 
Results  
 
In the eight participating countries, influenza peaked at different times – from week 5 in Italy and Poland to week 10 in 
Portugal (Figure 1).  
 
Figure 1. Influenza-like illness / acute respiratory infection rates by week of symptom onset as reported by the national 
sentinel systems, I-MOVE multicentre case–control study, study sites in eight European Union countries, influenza season 
2011/12  
 
 
A total of 16 vaccines were used at the country study sites, of which four were adjuvanted. The start of the country-specific 
vaccination campaigns ranged between 12 September 2011 (Poland) and 15 December 2011 (certain regions in 
Romania). A total of 1,057 practitioners agreed to participate in the study of which 747 (71%) recruited at least one patient, 
giving a total of 4,746 patients recruited (Table 1).  
Table 1. Participating practitioners and recruited influenza-like illness patients, by A(H3) influenza case–control status, 
vaccination status and study site, multicentre case–control study, study sites in eight European Union countries, 2011/12 
 
 
  
After exclusion of one individual who had received antivirals prior to swabbing, 21 individuals for whom laboratory results 
were missing, 10 individuals who received vaccination prior to the begin of the country's national vaccination campaign, 
170 individuals who did not adhere to the EU ILI case definition, 19 individuals who were swabbed more than seven days 
after symptom onset and 163 individuals who presented before or after the week of onset of the first and last influenza 
case respectively, 4,362 individuals met the study inclusion criteria. Among those, 2,084 were cases, of which 1,764 were 
positive for influenza A(H3) (84.6%), 30 were positive for influenza A(H1N1) (1.4%), 39 were influenza A unsubtypable 
(1.9%) and 251 were positive for influenza B (12.0%). As the analysis was restricted to the A(H3) subtype, the 320 
individuals who had an influenza type other than A(H3) were excluded. As the study site in Poland reported no A(H3) 
cases, all controls from this study site were excluded from the analysis (a further 112 records). An additional 18 individuals 
who presented before and after the first and last case of influenza A(H3) respectively were excluded. This gave a total of 
3,912 patients, of whom 1,033 (26.4%) were part of the target group for vaccination (Figure 2).  
 
Figure 2. Flowchart of data exclusion for pooled analysis, I-MOVE multicentre case–control study, study sites in eight 
European Union countries, 2011/12 
 
 
 
  
We included 1,016 ILI patients without missing information on seasonal vaccination (12 patients) or other covariates (five 
patients) in the IVE complete case analysis: 437 cases and 579 controls. A further eight patients from France with 
imprecise vaccination dates were excluded in the analysis by time since vaccination. 
 
The vaccination coverage in the studies was 35.9% (n=367) among the target group for vaccination and varied by study 
site from 12.8% (Romania) to 61.9% (Ireland). 
 
The median age was higher among cases (62.0 years; interquartile range (IQR): 37–70 years) than among controls (58.0 
years; IQR: 41–69 years) (Table 2). 
  
Table 2. Characteristics of A(H3) influenza cases (n=446) and test-negative controls (n=587) in vaccination target groups, 
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multicentre case–control study, seven European Union countries, week 46/2011–week 17/2012 
 
 
 
  
The proportion of cases presenting with any of the following symptoms was higher than controls: fever, malaise, myalgia 
and cough. A greater proportion of controls than cases had heart disease or at least one chronic condition. A greater 
proportion of controls visited their practitioner five or more times in the previous 12 months. A greater proportion of cases 
were swabbed within three days of symptom onset, but this was not statistically significant to the 5% level. The delay 
between vaccination and symptom onset was shorter for controls (median: 88.5 days, IQR: 64-115 days) than for cases 
(median: 116.0 days, IQR: 95-131 days). 
 
The Q test (p=0.142) and the I2 index (37.6%) testing for heterogeneity between the individual crude IVE estimates of the 
seven study sites included, suggested low to medium statistical heterogeneity. 
 
Crude IVE against A(H3) was 12.2% (95% CI: -17.2 to 34.2) and the adjusted IVE was 24.8% (95% CI: -5.6 to 46.5) 
(Table 3). Due to small sample size, an adjusted IVE was not interpretable among the individuals under 15 years of age. 
Among those aged between 15 and 59 years, the adjusted IVE was 63.3% (95% CI: 25.9 to 81.8) and 15.1% (95% CI: -
33.1 to 45.9) among those aged 60 years and over. 
 
Table 3. Pooled crude and adjusted 2011/12 seasonal influenza vaccine effectiveness against laboratory-confirmed A(H3) 
influenza in vaccination target groups, at study sites in seven European Union countries, week 46/2011–week 17/2012 
(patients with complete information, n=1,016) 
 
 
  
In the early phase of the season (week 46/2011 to week 6/2012) the adjusted IVE was 38.1% (95% CI: -7.9 to 64.5) and in 
the late phase -0.7% (95% CI: -59.8 to 36.5). The adjusted IVE among persons with onset of symptoms less than three 
months since vaccination was 46.8% (95% CI: 9.0 to 68.9) and the IVE among persons with onset of symptoms three 
months or more since vaccination was 10.5% (95% CI: –32.5 to 39.5) (Figure 3). 
Figure 3. Pooled adjusted 2011/12 seasonal vaccine effectiveness against laboratory-confirmed influenza A(H3) cases in 
vaccination target groups, by time since vaccination, at study sites in seven European Union countries, week 46/2011–
week 17/2012 (n=1,008) 
 
 
  
When restricting to the early influenza phase, IVE among persons with onset of symptoms less than 93 days since 
vaccination was 48.4% (95% CI: -3.5 to 74.3) and the IVE among persons with onset of symptoms 93 days or more since 
vaccination was 21.8% (95% CI: -64.2 to 62.8). When restricting to the late phase, IVE among persons with onset of 
symptoms less than 93 days since vaccination was -30.3% (95% CI: -287.7 to 56.2) and the IVE among persons with 
onset of symptoms more than 93 days since vaccination was 1.0% (95% CI: -60.5 to 38.9) (Figure 3). 
 
Discussion 
  
The overall adjusted pooled IVE estimates against influenza A(H3) from the multicentre case–control study in Europe 
among those targeted for vaccination was 24.8%, ranging between 15.1% in the elderly and 63.3% in persons aged 
between 15 and 59 years. This suggests a low adjusted IVE against medically attended A(H3) influenza among the target 
population except among younger adults. 
 
The A(H3) strain was also predominant during the 2008/09 season, the I-MOVE pilot season. In that season, persons 
aged 65 and above had an IVE of 56.4% (95% CI: -0.2 to 81.0) against A(H3) [5]. We observed a lower IVE in the 2011/12 
A(H3) dominated season with an IVE of 15.1% in those aged 60 years and above and an IVE of 12.4% in those aged 65 
years and above. 
 
The strength of this study lies in its multicentre nature, enabling recruitment of a large sample size of participants across 
the EU. It is possible to restrict to the target group for vaccination and to stratify further by influenza type and age. Study 
sites adhere to a common protocol and carry out systematic sampling. They also collect information on potentially 
important positive and negative confounders. In addition, data quality is very high with only 1.7% (n=17/1033) of records 
with missing data.  
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with missing data.  
 
Due to the observational nature of this study, we cannot exclude biases. We used a test-negative design, which is subject 
to the usual selection biases particularly for the control group. Study participants are selected according to a systematic 
sampling procedure by practitioners, who are blinded to the case and control status of the patients. This should minimise 
selection bias. 
 
As I-MOVE is based on existing sentinel networks, GPs recruited patients according to the case definitions used in their 
network: the EU ILI case definition or the ARI case definition. As the ARI case definition is a more sensitive case definition 
than the EU ILI one, we could restrict the analysis to patients meeting the EU ILI case definition for all patients included in 
the study.  
The test-negative design is a commonly used, but not validated study design [24–32]. Using test-negative controls is 
considered to adjust for healthcare-seeking behaviour more so than if community controls were selected, as vaccination 
coverage varies by healthcare-seeking behaviour [34,35]. In addition, the covariate ‘number of GP visits in the past 12 
months’ may adjust further for healthcare-seeking behaviour. Despite this adjustment, it is still debatable if test-negative 
controls properly reflect the vaccine coverage of the source population for cases [33]. 
 
While a higher proportion of controls visited their GP more frequently and had a chronic condition than cases, these 
variables were not strong confounders (-2% and 1% relative difference of IVE between model containing and not 
containing these confounders respectively). The main confounder was age group, changing the IVE of the adjusted model 
by 11%. 
 
We cannot exclude residual confounding, either by unmeasured confounders or by use of broad categories within given 
confounders. However, we used 10-year age bands to reduce residual confounding by age. While we used month of 
symptom onset as a covariate, the IVE differs only little if using week of symptom onset (24.8% compared to 23.4% for 
overall IVE). 
 
We included patients who were swabbed within seven days of symptom onset and we observed that a higher proportion of 
controls were swabbed more than three days after symptom onset than cases, although the difference is not statistically 
significant. The probability of influenza detection decreases with time between onset and swabbing, although the rate of 
decrease may vary by patient characteristics [35–38]. It is possible that some misclassification bias is introduced by 
including false negative controls through including patients with a greater delay between onset of symptoms and 
swabbing. However the difference is small if we compare our results to an analysis restricting the study population to 
persons swabbed three days or fewer since symptom onset (24.8% compared to 22.8% for overall IVE). 
 
Our study is limited by a small sample size for the stratified analyses. Therefore precise estimates were not always 
possible, particularly among the youngest age group, who are often the least numerous target group for vaccination. 
Estimates by influenza phase and by time since vaccination are also limited by the small sample size and although point 
estimates differ, confidence intervals overlap. 
 
The majority of countries participating in this study used both adjuvanted and non-adjuvanted influenza vaccines. The 
different vaccine types were used in different subpopulations. With the data collected for this study, it was not possible to 
identify the target groups to enable an estimate by vaccine type. 
 
IVE estimates arising from the total population were lower than the estimates from the target group for vaccination, e.g. 
overall adjusted IVE of 10.9% (95% CI: -16.2 to 31.7) among the total population (data not shown), compared to 24.8% 
(95% CI: -5.6 to 46.5) among the target group for vaccination. We believe that the target group for vaccination is a more 
homogeneous study population in relation to vaccination, the main exposure of interest, as study participants belonging to 
the target group for vaccination are likely to have a more equal access to vaccination than the total population.  
 
One limitation of restricting to this population is that it is identified through the practitioner questionnaires, which did not 
collect information on target group homogeneously across study sites. In particular information on healthy persons with 
professions targeted for vaccination may have been omitted from some countries. Despite these limitations, we believe 
that our study suggests a low adjusted IVE against medically attended A(H3) influenza among the target population except 
for among young adults in the 2011/12 influenza season.  
 
The lower IVE observed this season compared to the previous A(H3) dominated season (2008/09) may be due to changes 
in circulating viruses and hence suboptimal antigenic match between the 2011/12 vaccine and circulating strains. WHO 
and the Community Network of Reference Laboratories (CNRL) report northern hemisphere circulating A(H3N2) viruses 
being genetically and antigenically distinguishable from the A/Perth/16/2009 vaccine strain and being more related to 
A/Victoria/361/2011-like reference viruses, differences which may have increased along the season [18,39]. This 
virological change could have contributed to the lower IVE in the latter part of the season.  
 
As the 2011/12 influenza season was a late season, persons presenting with influenza had a long delay between onset of 
symptoms and the vaccination, as campaigns were carried out in the autumn of 2011. The observed fall in IVE may also 
be due in part to waning of the immunity induced by the vaccine, perhaps markedly so in older people [40–43]. Persons 
vaccinated less than 93 days before symptom onset showed a higher IVE than persons vaccinated 93 days or more 
before symptom onset. However, persons vaccinated 93 days or more before symptom onset were more likely to present 
later in the season, co-temporal with the emergence of antigenically drifted influenza viruses. To disentangle the possible 
effects of waning immunity and antigenic drift, we looked at IVE by early and late influenza phase. In the early influenza 
phase IVE was higher among persons vaccinated less than 93 days before symptom onset compared to persons 
vaccinated 93 days or more before symptom onset. This was not the case in the late influenza phase, where we may 
expect a greater effect of antigenic drift on the IVE estimates. This suggests the waning immunity hypothesis may be 
plausible. 
 
In conclusion, the I-MOVE multicentre case–control study suggests a low IVE against medically attended A(H3) influenza 
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In conclusion, the I-MOVE multicentre case–control study suggests a low IVE against medically attended A(H3) influenza 
in the 2011/12 season. The I-MOVE multicentre case control study provides high quality and rapid IVE estimates and 
should supplement the virological information that informs the WHO recommendations on vaccine strain selection [6,8]. It 
is difficult to disentangle the respective roles of changes in the circulating viruses, possible waning immunity and otherwise 
imperfect vaccine. Further virological studies are needed on an annual basis quantifying drift over time as well as large 
epidemiological studies by time since vaccination with several delay categories to fully understand these potentially 
important issues. Production of an improved seasonal influenza vaccine with greater effectiveness should be given a high 
priority.  
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